Simon N.r. Harford - 19 Jan 2023 Form 4 Insider Report for ALBIREO PHARMA, INC.

Role
CFO and Treasurer
Signature
/s/ Jason Duncan, Attorney-in-fact
Issuer symbol
N/A
Transactions as of
19 Jan 2023
Net transactions value
-$77,789
Form type
4
Filing time
20 Jan 2023, 15:05:14 UTC
Previous filing
25 Oct 2022
Next filing
23 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALBO Common Stock Sale $77,789 -1,776 -5.1% $43.80 32,791 19 Jan 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
F2 Represents 13,497 shares of common stock and 19,294 restricted stock units. Includes 1,272 shares of common stock acquired under the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan (the "ESPP") on November 30, 2022.